Daple protein has mixed impacts on colorectal cancer
Researchers have discovered a cell signaling pathway that appears to exert some control over initiation and progression of colorectal cancer, the third leading cause of cancer-related death in the United States. A key protein in the pathway also appears to be predictive of cancer survival rates. The study was reported in eLife (2015; doi:10.7554/eLife.07091).
The protein, known as Dishevelled-associating protein with a high frequency of leucine residues (Daple) is produced by nearly all healthy cells in the body. It is well-recognized for its role in helping cells in different tissues coordinate processes, such as development and maintenance of organs.
The study is the first to show that Daple is also a tumor suppressor, though only in the early stages of cancer. At later stages of disease, when cancer cells have escaped from the main tumor and are circulating in the blood stream, the protein may actually make cancer cells more invasive and likely to spread.
“Daple is a double-edged sword,” said senior author Pradipta Ghosh, MD, an associate professor at University of California, San Diego School of Medicine in San Diego, CA. “The protein is a tumor suppressor early on but heralds faster death in advanced stages of colorectal cancer. We are working to figure out why.”
For the study, researchers analyzed tumor samples from 173 persons with stage 2 colon cancer for Daple levels. Among these people, lower Daple levels were associated with worse outcomes over a 2 year period, while higher levels were associated with better patient survivorship over the same period.
Daple levels were then measured in cancer cells collected from the blood stream of 51 patients with stage 4 colorectal cancer. Among these patients with late-stage cancer, those with high Daple levels had a 20% survivorship over a 1,000-day period, compared with a 100% survivorship for those with low Daple levels. By the 3 year mark, there were no survivors in the high-Daple group. In contrast, among those with low-Daple expression, 75% of the patients were still alive.
Consistent results were observed during three-dimensional tumor cell culture tests. Reduced expression of Daple aided tumor formation and growth, while increased Daple expression triggered cancer cell motility, associated with metastasis.
Fluorescent imaging studies of cells showed that Daple functions primarily by regulating the activity of a family of cell-signaling proteins, known as G proteins. G proteins enable cells to sense and respond to what is happening around them. About 30% of all prescription drugs affect cells via G-protein-coupled receptors.
Most likely, it is G protein signaling that conveys both the desirable tumor-suppressing effects and the not-so-desirable tumor-spreading effects. The consequences of this G signaling on a patients with cancer's prognosis thus depends on where and when the G signaling occurs.
“Our next challenge is to figure out how we can exploit Daple's beneficial attributes while inhibiting its negative ones,” Dr. Ghosh said.